Biotalys Raises 12.05 Million Euros Through Private Placement with a 40% Discount
Biotalys announced on Wednesday the successful completion of a private placement with its existing shareholders, raising 12.05 million euros. The transaction involved the issuance of 7,875,811 new shares at 1.53 euros each, representing a capital increase of approximately 20.96%.
Funding Reserved for Reference Investors
The private placement engaged institutional and strategic investors already part of the capital: Ackermans & van Haaren NV, Agri Investment Fund BV, ASR Vermogensbeheer NV, Federale Participatie- en Investeringsmaatschappij NV, Gimv NV, PMV NV, Sofinnova Industrial Biotech I, and the Flanders Institute for Biotechnology (VIB). The issue price of 1.53 euros per share represents a 40% discount compared to the weighted average of the stock prices over the last thirty days of trading (from April 1 to April 30, 2026).
New shareholders have committed to a three-month lock-up period for their shares (both new and old) starting from the closure of the transaction. The delivery of the securities is scheduled around May 20, 2026, from which date the new shares will be admitted for trading on Euronext Brussels.
Allocation of Funds and Strategic Milestones
Biotalys plans to use the proceeds from this capital raise to support the development of its precision biocontrol solutions based on proteins, aimed at the crop protection markets before and after harvest. The company is targeting several milestones in the near future: regulatory approval of Evoca in the European Union, product registration in California, conducting field trials with a leading candidate from the BioFun-6 range, optimizing its production process in partnership with 21st.BIO, and continuing existing collaborations with Syngenta, the Gates Foundation, and its partner AgroFresh in the post-harvest market.
